8-K: Verona Pharma Acquired by Merck, Delists Nasdaq

Verona Pharma plc has completed its acquisition by Merck Sharp & Dohme LLC, with shareholders receiving $13.375 per ordinary share or $107 per ADS, leading to its delisting from Nasdaq.

Summary

• Verona Pharma plc (the "Company") has been acquired by Merck Sharp & Dohme LLC ("Merck") and its subsidiary Vol Holdings LLC ("Bidco") through a court-sanctioned English law scheme of arrangement.
• The acquisition was consummated on October 7, 2025, following the High Court of Justice of England and Wales sanctioning the Scheme of Arrangement on October 6, 2025.
• Holders of Company Shares received $13.375 in cash for each share.
• Holders of Company American Depositary Shares (ADSs), each representing 8 ordinary shares, received $107 in cash for each Company ADS.
• Outstanding Company share options, time-based restricted share units, and performance-based restricted share units were converted into cash payments based on the ADS Consideration, with performance-based units deemed achieved at the maximum level.
• Trading of Company ADSs (Nasdaq: VRNA) on the Nasdaq Global Market was suspended effective as of the open of trading on October 7, 2025.
• The Company intends to file Form 25 to delist and deregister Company ADSs and Form 15 to terminate registration of all Company Shares and ADSs, suspending its reporting obligations under the Exchange Act.
• As a result of the transaction, Verona Pharma plc became an indirect wholly-owned subsidiary of Merck.
• All previous directors of the Company resigned, and new management was appointed on the Closing Date.

Sentiment

Score: 8

Explanation: The sentiment is highly positive for shareholders who received a cash payout for their shares/ADSs. The completion of the acquisition provides certainty and liquidity. For the company, it signifies a successful exit and integration into a larger pharmaceutical entity.

Positives

• Shareholders received a cash consideration of $13.375 per ordinary share or $107 per ADS, providing a clear exit and liquidity.
• Outstanding equity awards (share options, restricted share units) vested and were converted into cash, benefiting employees and executives.
• The completion of the acquisition resolves any uncertainty regarding the transaction's closing, providing finality for investors.

Negatives

• Verona Pharma plc ceases to exist as an independent publicly traded company.
• Company ADSs have been delisted from Nasdaq, removing public trading opportunities for investors.
• The Company will no longer have independent reporting obligations under the Exchange Act.

Risks

• The primary risk associated with the non-completion of the previously announced acquisition has been resolved.
• No new specific risks are introduced by the completion of the acquisition itself, as the company is now a private subsidiary.

Future Outlook

Verona Pharma plc will operate as an indirect wholly-owned subsidiary of Merck, and as such, its independent future outlook as a public entity is no longer applicable. The company will no longer provide forward-looking statements or guidance to public investors.

Industry Context

This acquisition reflects a continuing trend in the pharmaceutical and biotechnology industry where larger established companies like Merck acquire smaller, innovative firms to expand their pipeline and market presence. Such transactions often provide a strategic exit for the acquired company's shareholders and integrate promising assets into a broader R&D and commercialization framework.

Management Changes

Corporate Governance

Legal Proceedings

• The High Court of Justice of England and Wales sanctioned the Scheme of Arrangement at a public hearing on October 6, 2025, which was a necessary legal step for the acquisition's completion.

Stakeholder Impact

• Shareholders: Received cash consideration for their shares/ADSs, providing liquidity and a return on investment.
• Employees (Management): Previous directors resigned, and new management was appointed, indicating a change in leadership structure.
• Company as an entity: Ceases to be an independent public company and becomes part of a larger corporate structure under Merck.

Next Steps

• The Company will file a Form 25 with the SEC to delist and deregister its ADSs from Nasdaq.
• The Company intends to file a Form 15 with the SEC to terminate the registration of its shares and ADSs and suspend its reporting obligations under the Exchange Act.

Key Dates

Recommendation

The company has been acquired by Merck and its American Depositary Shares (ADSs) have been delisted from the Nasdaq Global Market. Existing shareholders would have received a cash payout for their shares/ADSs. There is no longer a public market for the stock, so any remaining shares would be subject to the terms of the acquisition and no longer trade publicly. Therefore, for any investor still holding shares, the effective action is a 'sell' as the transaction has concluded and cash has been distributed.

Keywords

Verona Pharma, Merck, Acquisition, Scheme of Arrangement, Delisting, VRNA, Pharmaceutical, Biotech, Merger, Nasdaq